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Abstract 
Objectives: Changes in clot microstructure are increasingly implicated in the 
pathology of atherosclerosis although most data are from techniques in the remote 
laboratory using altered blood.  We validate the novel biomarker Gel Point in STEMI 
patients and assess therapeutic interventions. Gel Point marks the transition of blood 
from a visco-elastic liquid to visco-elastic solid and is rapidly measured using 
unadulterated blood. The Gel Point provides measurements of clot microstructure 
(df), clot strength (G`GP), and clot formation time (TGP). 
Methods: We prospectively recruited 38 consecutive patients with STEMI 
undergoing primary percutaneous coronary intervention (pPCI). Venous blood 
samples were collected on admission, after pPCI and 24h after admission for 
assessment of the new biomarkers, standard coagulation tests and scanning 
electron microscopy (SEM).  
Results: df after pPCI was significantly lower than df on admission (mean 1.631 [SD 
0.063] vs 1.751 [0.052], p<0.000001) whereas df at 24h was similar to that on 
admission. G`GP also showed similar trend to df (p<0.001). TGP was significantly 
prolonged at after-PCI measurement compared with admission (median 854 s [IQR 
581–1801] vs 217 [179–305], p<0.00001). Changes in the values of df and G`GP  
reflect the changes in the SEM images of the mature clot.  
Conclusions: We characterise Gel Point derived markers of clot microstructure in 
patients admitted with emergency arterial thrombosis. This reproducible point of care 
test can be safely performed at pPCI and demonstrates a quantifiable response to 
clinical therapies. 
Key words: Percutaneous coronary intervention, acute myocardial infarction, drug 
monitoring, fractal dimension, gel point, coagulation  
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Introduction 
Changes in clot microstructure and viscoelastic properties are increasingly 
recognized as important mechanisms underlying pro-thrombotic disease.[1-4] We 
have recently reported a novel point of care viscoelastic technique that provides 
three related biomarkers all calculated from one measurement at the Gel Point (GP); 
clot formation time (TGP), clot strength (G`GP) and clot microstructure quantified by 
fractal dimension (df).[2,5,6] Importantly, in contrast to many assays in routine clinical 
use, the measurement is performed using unadulterated whole blood, in a near 
patient setting and provides rapid assessment of coagulation. This technique has 
been validated in healthy volunteers and suffers of venous thromboembolism,[2,5] 
however, has yet to be investigated in arterial thrombosis and the hospital inpatient 
emergency setting. 
 
In myocardial infarction abnormal thrombus microstructure formation has been 
associated with both premature coronary atherothrombosis and adverse events 
following primary percutaneous coronary intervention (pPCI).[7-10] Previous studies 
of clot microstructure however have relied mostly on multiple analytical and imaging 
techniques on processed samples in remote laboratories, limiting potential for 
translation into clinical use. In contrast, the GP biomarkers provide a rapid single test 
in unadulterated blood. 
 
The current gold standard treatment of ST elevated myocardial infarction (STEMI) is 
to restore coronary flow by mechanical thrombus disruption or removal in 
combination with adjunctive antithrombotic therapy which includes a variety of anti-
platelet and anticoagulants.[11] Balancing the inherent bleeding risk of potent 
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antithrombotics against their proven anti-ischemic benefits remains a major 
challenge to the cardiac community.[12]  
 
The present study investigates whether GP biomarkers can be safely and feasibly 
obtained in the setting of emergency time-dependent clinical care and reproducibly 
measure the effect of antithrombotic therapy in pPCI.  
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Materials and Methods 
 
Study Design and Population Group 
This study complies with the declaration of Helsinki and was approved by a local 
Research Ethics Committee (Wales Research Ethics Committee 6; REC Number 
07/WMW02/34). Adult (≥18 years) patients with STEMI admitted to undergo primary 
pPCI were recruited at a large teaching hospital in South Wales. For those unable to 
consent due to need of emergency treatment, consent was sought retrospectively. 
Informed written consent was obtained from all participants and confirmation of 
ongoing consent was reiterated at 24 hours. Exclusion criteria included any other 
form of anticoagulation prior to hospital admission, or those with any known blood 
dyscrasia.  
 
Prior to pPCI all patients received 300mg of aspirin, 600mg of clopidogrel and 
between 2000-5000 IU of unfractionated heparin. A bolus of Bivalirudin (0.75mg/kg) 
was given followed by an infusion (1.75mg/kg/h). During catheter angiography the 
initial flow in the infarct related artery prior to any percutaneous intervention was 
noted using the TIMI grading system with grade 1 indicating no anterograde flow 
through the occlusion and grade 3 indicating normal flow.[13] All patients continued 
to receive 75mg of aspirin and 75mg of clopidogrel commencing 24 hours after the 
procedure.  
 
For the study three samples of blood were taken from the patients, the first taken on 
admission following the 300mg of aspirin (usually given pre-hospital by ambulance 
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paramedic protocol) but before administration of clopidogrel, heparin or Bivalirudin 
(point A). The second sample was taken immediately after the pPCI procedure (point 
B) with the third on the following day after the (75mg) aspirin and clopidogrel had 
been administered (point C).  
 
Blood Sampling 
One 20ml sample of venous blood was obtained at point A, B and C respectively. 
For each of the 3 samples the blood was divided into several aliquots. One aliquot of 
whole venous blood was immediately transferred to a rheometer for testing (see 
Rheometric Measurements: The Gel Point). The remaining aliquots were used to 
perform standard coagulation screens, complete blood counts (CBC) and platelet 
function analysis. A small aliquot (20µl) of blood was taken to obtain SEM images of 
whole blood mature clots formed ex vivo. 
 
Rheometric Measurements: The Gel Point 
The haemorheological biomarkers (TGP, G`GP & df) which are the focus of this study 
are obtained from the Gel Point (GP) technique from which the fractal dimension of 
the clot is determined.[14-18] The GP technique has been previously validated for 
use with blood in several studies.[2,5,6] The GP marks the transition of the blood 
from a viscoelastic liquid to a viscoelastic solid. In the present study a 6.6 ml aliquot 
of whole unadulterated venous blood was loaded into a double-gap concentric 
cylinder measuring geometry of a TA Instruments AR-G2 (TA Instruments, New 
Castle, DE, USA) controlled-stress rheometer (at 37°C ± 0.1ºC) in a near patient 
setting and tested immediately to obtain the GP.[6] 
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Computational Analysis  
Previous studies using light scattering and microscopy have established that 
incipient fibrin clots have fractal properties, where the mass, M, is related to df by the 
following power law equation [M ≈ ɛdf, where ɛ is some length scale value in the 
range 100nm to 10μm] this relationship is used to illustrate the how changes in df 
relate to changes in mass.[19] 
 
Scanning Electron Microscopy (SEM) 
SEM was used to image micrographs of mature formed clots at the three sample 
points for 3 individuals, clots that were fixed, dehydrated, critical point dried and 
coated with gold-palladium.  All clots were prepared following a standardised 
protocol.[20] Samples at each time point were allowed to clot at 37°C. All samples 
were then washed three times with 2 cocadylate buffer pH 7.2 for the removal of 
excess salt and fixed for a minimum of 4 hours in 2% glutaraldehyde solution. The 
clots were rinsed with cocadylate buffer and dehydrated in a series of ethanol 
concentrations from 30 to 100%.  The clots were critical point dried with 
hexamethyldisilazane for 45 minutes and placed in a fume hood for 24 hours.  They 
were then mounted to 0.5” SEM stubs (agar scientific, UK) and sputter coated with 
gold palladium. All samples were investigated with a Hitachi S4800 scanning 
electron microscope (Hitachi, High-Technologies Corporation, Tokyo, Japan).  
 
Laboratory Markers 
A 4 ml aliquot of blood was used for CBC analysis, samples being collected into 
plastic, full-draw dipotassium EDTA Vacuettes (Greiner Bio-One, Stonehouse, UK 
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Ref: 454286). FBC was analyzed using a Sysmex XE 2100 (Sysmex UK, Milton 
Keynes, UK) automated haematology analyser within 2 hours of collection. 
 
An additional 4.5ml was used for routine coagulation studies, being transferred 
immediately into citrated silicone glass Vacutainers (0.109M) (Becton-Dickinson, 
Plymouth, UK Ref: 367691). Prothrombin Time (PT), activated partial thromboplastin 
time (APTT) and Clauss fibrinogen were measured using a Sysmex CA1500 
analyser within 2 hours of collection. Fibrinogen calibration was verified against the 
2nd International Fibrinogen Standard Version 4 (NIBSC code 96/612). All reagents 
were obtained from Siemens, (Frimley, UK). All testing was performed within 2 hours 
of sample collection.  
 
Platelet aggregation Measurements  
Measurement of platelet aggregation was achieved using the Multiplate analyser 
(Dynabyte GmBH, Munich, Germany) to explore the effect of platelet function on df. 
An aliquot of whole blood (3ml) was transferred to hirudin tubes (Roche Diagnostics 
GmbH, Mannheim, Austria Ref: 06675751) and kept at room temperature for 30 
minutes before testing. For analysis, 300 μl of whole hirudinated blood was added to 
300 μl of saline pre-heated to 37°C and allowed to incubate for 3 minutes in 
individual test cells. Following incubation platelet activation was induced by addition 
of specific agonists, to respective test cells and electrical impedance was recorded. 
The agonists tested included adenosine diphosphate (ADP, 20 μl of 0.2mM stock 
solution) which triggers platelet activation via platelet ADP receptors.  The most 
important receptor of ADP is P2Y12 receptor, which is inhibited by clopidogrel and 
other thienopyridines. The second was the ASPI test reagent (20 μl of 15 mM stock 
 9 
 
solution) which contains arachidonic acid, a substrate of the platelet enzyme 
cyclooxygenase. Cyclooxygenase transforms arachidonic acid into thromboxane A2, 
a platelet activator. Aspirin blocks cyclooxygenase thereby inhibiting platelet activity 
and ASPI induced aggregation.  
 
Statistical analysis  
Descriptive analyses were performed to establish baseline characteristics. Results 
are reported as mean (±SD) unless otherwise stated. The normality was assessed 
using normal probability plots and Shapiro–Wilk test.  Wilcoxon signed-rank and two 
sample t-test were used to compare differences between two time points and one 
way ANOVA with Tukey’s pairwise analysis was used to compare differences across 
all sampling points. Spearman's correlation analysis was done to explore any 
associations between various tests as defined from the start of symptoms to the time 
blood was taken. Differences were assumed to be significant at p<0.05 and actual 
probability values are quoted when deemed significant. Minitab version 16 software 
(Havertown, PA) was used to perform the analysis. 
 
 
 
 10 
 
 
Results  
Patient and angiographic data 
Forty-five patients with suspected STEMI were screened between January 2012 and 
April 2014. Seven subjects were excluded: 2 not STEMI as diagnosis, 2 received 
anticoagulants in the lab prior to  testing, one on established warfarin therapy, one 
technical failure and one withdrew consent for the second sample. Thirty-eight 
patients were confirmed to have STEMI and included in this analysis. Baseline 
characteristics of the patients and angiographic data are presented in Table 1.  
 
Gel Point Biomarker 
A significant change (p<0.001) in df is observed between point A, pre-pPCI (1.751 ± 
0.052) and point B, immediately post-pPCI (1.634 ± 0.058). At point C, 24hours later, 
the df returns to a value similar to point A (1.742 ± 0.041) (Figure 1). This effect is 
mirrored in the changes observed for G`GP (Table 2), with a significant difference at 
point B compared to point A (p<0.001). The TGP shows a significant increase in value 
(p<0.001) at point B (from 238 ± 93 sec at point A to 1310 ± 1014 sec at point B), 
before returning to 245 ± 95 sec at Point C. There is a significant change in df 
associated with treatment (p<0.0005, one-way ANOVA) with Point B being 
significantly lower than both the first and the 3rd when the data was analysed by 
Tukey’s pairwise method. Exactly the same can be said about G`GP. However, for 
TGP,  Point B is significantly greater than both A and C. 
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Table 1: Patient Baseline Characteristics and Procedural Details 
Patient Characteristics 
Age  69.3±14.6 
Male 23(60.5%) 
Current Smoker 7(18.4%) 
Hypertension 16(42.1%) 
Diabetes Mellitus 6(15.8)%) 
Dyslipidaemia 13(34.2%) 
Previous MI 2(5.3%) 
Cardiogenic Shock 1(2.6%) 
    
Procedural Details 
Infarct Related Artery   
           LAD 17(44.7%) 
           LCX                                                 8(21.1%) 
           RCA 13(34.2%) 
Ischaemia Time (mins)  240 (240-345) 
Syntax Score 19.9(±13.5) 
Lesion Success (residual 
stenosis <50%/TIMI≥2) 
34(89.5%) 
Thrombus Aspiration 19(50.0%) 
No of Stents (%Drug 
Eluting) 
1.1(±0.7) 
(77.5%) 
Occluded artery (TIMI 0) at 
presentation 
19(50.0%) 
TIMI 3 flow at presentation 11(28.9%) 
TIMI 3 flow after PCI 27(71.1%) 
Gp2b3A Inhibitor use 1(2.6%) 
28 Day Mortality 4(10.5%) 
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Figure 1: Fractal Dimension, df: box and whisker plot illustrating the change in df 
for the three different time points measured for the STEMI patients (n=38); Point A 
(pre-pPCI), Point B (post-pPCI) and Point C (24 hours).  The Star’s represents the 
mean value of the data for each time point (Point A:1.751 ± 0.052; Point B: 1.634 ± 
0.058 and Point C 1.742 ± 0.041). *denotes a significant change in df associated with 
treatment (p<0.0005, one-way ANOVA) with Point B being significantly lower than 
both Point A and Point C when the data was analysed by Tukey’s pairwise method. 
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Table 2: Table of the Gel Point, standard markers of haemostasis and platelet 
aggregometry. * denotes a significant deviations from the baseline Point A values as 
detected by one way ANOVA and Tukey’s pairwise analysis; where p<0.05. 
  Pre-PCI (Point A) Post-PCI (Point B) 24 hour (Point C) 
GelPoint 
(Median(IQR)       
TGP (sec) 217(179-305) 854(581-1801)* 225(181-288) 
G`GP (Pa) 0.044(0.040-0.054) 0.027(0.019-0.032)* 0.044(0.039-0.056) 
        
Coagulation Screen       
PT (sec) 
10.9±0.86 
43.5±19.57
*
 
10.6±0.59 
APTT (sec) 27.3±11.87 157.7±79.22* 26.6±5.89 
Fib(Clauss) (g/l) 3.5±0.67 2.7±0.63* 3.9±0.61 
        
Full Blood Count       
Platelet Count (x109) 249±86 241±78* 265±76 
Haemoglobin (g/l) 13.8±1.57 12.9±1.29 13.3±1.57 
Haematocrit (l/l) 0.409±0.036 0.391±0.034* 0.398±0.045 
        
Multiplate 
(Median(IQR))       
ADP AUC 94(76-123) 100(72-125) 28(16-55)* 
ASPI AUC 24(16-43) 25(15-39) 12(8-16) 
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Standard coagulation markers 
The standard coagulation, FBC and fibrinolysis markers are presented in Table 2. A 
significant reduction in fibrinogen concentration and a significant prolongation of PT 
and APTT were observed at point B compared to point A and C. 
 
Platelet aggregometry  
The platelet aggregometry results are shown in Table 2. All patients received aspirin 
at least 60 minutes before first sample collected. The ASPI AUC results at point A 
and B were both found to me well below the stated normal range quoted by the 
manufacturer (75-115U) indicating the high loading dose of aspirin (300mg) given to 
patients prior to admission to hospital is reducing platelet activity. We found no 
evidence of low responders to aspirin at point C (24 hours) in this study with all 
patients showing an ASPI AUC result of less than 40U.[21] Clopidegral was given 
just before sampling point B, as a result no reduction in the ADP AUC values were 
recorded at points A & B as the drug is either absent or not had sufficient time to 
work. The ADP AUC values are reduced at point C in the majority of patients, 
however there are 8 patients that would be classified as low responders. Having 
ADP AUC values above 47U, previously classified as a cut off for low responders to 
clopidegral in patients who have received PCI.[22] 
 
Comparison between SEM images of mature clot microstructure and 
templating effect of df 
Analysis of the SEM micrographs was based on visual inspection of the images of a 
particular patient at Point A, B & C (See Figure 2) The images show little difference 
between point A and C; with fibre width, fibre density and pore space all being 
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similar. The image of point B (Figure 2) in comparison to Point A & C illustrates 
reduced fibre width and density. The results of the rheological analysis 
corresponding to these images are: A) df = 1.739 (G`GP= 0.061Pa; TGP=247), B) df = 
1.650 (G`GP= 0.021Pa; TGP=3120sec) and C) df = 1.727 (G`GP= 0.056Pa; TGP=247).  
 
 
Figure 2 – Representative SEM micrographs of fully formed blood clots taken 
from the same individual at three different time intervals: Point A (pre-pPCI), 
Point B (post-pPCI) and Point C (24 hours). The images show a change in the clot 
microstructure characteristics, where at point B the clot has reduced fibre width and 
density when compared to Point A and C. The scale bar applies to all three images 
and is 10 µm long. The image at Point A corresponds to a df of 1.739, with a df of 
1.650 at Point B and 1.727 at Point C.  
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Discussion 
The GP biomarkers may have potential as a future tool in cardiac risk stratification, 
by providing a single test to better assess the effects of antithrombotic therapy which 
may improve patient outcome by providing a more individually tailored therapeutic 
approach. We present the first data investigating a novel biomarker of clot 
microstructure, Gel Point, in the hospital setting of STEMI patients undergoing pPCI. 
Gel Point biomarkers can be safely and rapidly obtained in emergency clinical areas 
including the cardiac catheter laboratory and coronary care unit, without disruption or 
time delay to clinical care pathways, demonstrating potential as a useful clinical tool.  
 
Therapeutic intervention using anti-platelets and thrombin inhibitors results in a 
significant reduction in df (from 1.751 ± 0.052 at point A to 1.634 ± 0.058 at point B, 
p<0.000010). This is consistent with our previous observations of a reduction of df in 
healthy volunteer blood by the addition of heparin in vitro and in venous thrombo-
embolism (VTE) outpatients receiving oral anticoagulants.[2,5] On day 1 post pPCI 
following clearance of peri-procedural anti-thrombotic df increases to 1.742 ± 0.041. 
  
To fully appreciate what these changes in df represent, it is useful to consider a 
relationship between df and the amount of fibrin mass structurally organized within 
the clot.[19] Figure 3 illustrates the non-linear relationship between df and mass, 
where a clot with a df of 1.84 (the highest single value of df obtained in the study) 
incorporates approximately 4 times the amount of mass than a clot formed with a df 
of 1.74. Whereas, a reduction in df from 1.75 (Point A) to 1.63 (point B- post 
treatment) would result in a 75% decrease in clot mass.  The structural and mass 
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changes between point A and B would result in very different structures being 
formed, we illustrate this with the images shown in Figure 3. This is an important 
finding considering previous studies have shown the significant role clot 
microstructure has on fibrinolysis. [23,24]  The images provided in Figure 3 are 
representative of different fractal structures with df values of 1.63, 1.75 and 1.84. 
These images clearly show a significant difference in the structures of the clots 
formed over this range, the high density of red (nodes) in the 1.84 images indicates a 
higher density of mass in that area with a large amount of inter connectivity creating 
a very strong clot. As df is reduced the number of these dense areas (red) will reduce 
where at 1.75 there are only a handful of red areas and at 1.63 there are barely any. 
Consequently these clots will mechanically weaker and more highly friable. These 
observations are supported by the by the significant positive correlation between df 
and G`GP (p<0.001), the highest values of df corresponding to the highest values of 
clot strength, taking the elastic modulus, G`GP, as analogous to that of clot ‘strength’.  
 18 
 
 
Figure 3 – Graph of df vs. Mass. Illustration of the non-linear relationship between 
df and the amount of mass, incorporated into the structure. Substantial increases in 
mass are required to generate small increments of df. The mass value on the y-axis 
is normalised for the healthy index value of df (=1.74). Illustrations of different 
incipient clot microstructures at particular values of df are provided (cross = 1.63, 
circle = 1.75 and square = 1.84 respectively). The colour of each node (unit sphere) 
within the fractal represents the local density of constituent nodes within a sphere of 
radii 5 units, the colour ranges from green (1 neighbouring node) to red (20 
neighbouring nodes). 
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It has been previously suggested that only some 15-20% of the total available 
fibrinogen is estimated to be incorporated within the incipient clot, an important 
consideration when taking into account further clot development.[25] A recent study 
involving analysis of viscoelastic and imaging data has established that the incipient 
clot acts as a template for ensuing clot development.[17] The results herein show 
that incipient clot microstructure (df) mirror the changes observed in the mature clot 
(SEM images). Little change is observed when comparing the images Figure 2a & 2c 
(point A and C), the values of df and G`GP recorded at these points were also similar 
(1.739 to 1.727 and 0.061Pa to 0.059Pa respectively). In contrast the clot shown in 
Figure 2b (point B) illustrates a change to thinner fibres and significantly less 
crosslinking and density which corresponds to a decrease in both df and G`GP (1.650, 
0.021Pa) and an increase in TGP from 247sec to 3120sec.  
 
Non-response to anti-platelet therapy is an area of clinical concern with patient 
resistance up to 45% with aspirin and 35% with clopidogrel and an increased 
thrombotic risk.[26-28] In the present study we found no patients were aspirin 
resistant, however, at point C (24 hours after PCI) 8 patients are shown to be 
clopidegral low responders. Interestingly the mean df of these 8 patients was 1.761 ± 
0.0331 compared to the rest of the group whose df was 1.735 ± 0.0428 (p=0.11).This 
highlights the need for larger studies assessing the link between platelet function and 
df, where ineffective antiplatelet therapy may be detected by df.  
 
Limitations of the study included the inability to investigate the individual effect of the 
therapeutic interventions as many are given simultaneously or to catch the patients 
when they were treatment naive. Due to current care pathways each patient is given 
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a standard dose of 300mg aspirin en route to hospital. Thirdly, this study employed 
convenience sampling due to practical issues. However all patients were screened 
and considered for inclusion in the study when a researcher was available and 
baseline characteristics of the study participants is reassuring as it reflects what is 
expected in this patient population.  
 
In summary we present the first data investigating Gel point biomarkers in STEMI 
patients undergoing pPCI. The management of acute coronary syndromes (ACS) 
requires a fine clinical balance of anticoagulation to treat pathological thrombus 
burden (efficacy) with the risks of bleeding, (safety).[12] Response to antiplatelet and 
anticoagulant therapy has significant inter-individual variation.[11]  This study 
identifies that therapeutic intervention in STEMI patients with drugs given during 
pPCI has significant effects on clot microstructure, clot strength and the clot 
formation time as measured at the GP by df, G`GP and TGP. Further investigations of 
bedside df, G`GP & TGP in ACS patients are required to determine how this novel 
biomarker might have a role in determining optimum individual patient tailored 
therapy.  
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